Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms

Hematology/Oncology Clinics of North America

Volumn 26, Issue 5, 2012, Pages 1083-1099

  Santos, Fabio P S ^a   Verstovsek, Srdan ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Essential thrombocythemia; JAK2 inhibitor; JAK2 V617F; Myelofibrosis; Polycythemia vera

Indexed keywords

ACETYLSALICYLIC ACID; BMS 911453; BREAKPOINT CLUSTER REGION PROTEIN; GAMMA INTERFERON; GANDOTINIB; HEAT SHOCK PROTEIN 90; HETEROCHROMATIN PROTEIN 1; HYDROXYUREA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; LENALIDOMIDE; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NS 018; PACRITINIB; PANOBINOSTAT; PEGINTERFERON ALPHA2A; PLACEBO; PROTEIN BCL XL; PROTEIN KINASE TYK2; RUXOLITINIB; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANEMIA; CARCINOGENESIS; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DIMERIZATION; DIZZINESS; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; EPIGENETICS; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HEADACHE; HUMAN; HYPERURICEMIA; IC 50; INTRACELLULAR SIGNALING; LEUKOCYTOSIS; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; TUMOR LYSIS SYNDROME;

HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; PROTEIN KINASE INHIBITORS;

EID: 84866621614     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.07.008     Document Type: Review

References (81)

1. Thiele J., Kvasnicka H.M., Tefferi A., et al. Primary myelofibrosis. World health organization classification of tumours of haematopoietic and lymphoid tissues 2008, 44-47. IARC Press, Lyon (France). S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
2. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
3. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
4. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
5. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
6. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
7. Plo I., Nakatake M., Malivert L., et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008, 112:1402-1412.
8. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
9. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
10. Anand S., Stedham F., Gudgin E., et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood 2011, 118:1610-1621.
11. FDA approval of ruxolitinib. Available at: Accessed on April 10, 2012. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm280155.htm.
12. Wilks A.F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A 1989, 86:1603-1607.
13. Giordanetto F., Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002, 15:727-737.
14. Wilks A.F., Harpur A.G., Kurban R.R., et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991, 11:2057-2065.
15. Saharinen P., Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277:47954-47963.
16. Ungureanu D., Wu J., Pekkala T., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011, 18:971-976.
17. Leonard W.J., O'Shea J.J. Jaks and STATs: biological implications. Annu Rev Immunol 1998, 16:293-322.
18. Rodig S.J., Meraz M.A., White J.M., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
19. Neubauer H., Cumano A., Muller M., et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397-409.
20. Parganas E., Wang D., Stravopodis D., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93:385-395.
21. Nosaka T., van Deursen J.M., Tripp R.A., et al. Defective lymphoid development in mice lacking Jak3. Science 1995, 270:800-802.
22. Thomis D.C., Gurniak C.B., Tivol E., et al. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995, 270:794-797.
23. Russell S.M., Tayebi N., Nakajima H., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995, 270:797-800.
24. Karaghiosoff M., Neubauer H., Lassnig C., et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000, 13:549-560.
25. Shimoda K., Kato K., Aoki K., et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000, 13:561-571.
26. Luo H., Rose P., Barber D., et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 1997, 17:1562-1571.
27. Akada H., Yan D., Zou H., et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115:3589-3597.
28. Bumm T.G., Elsea C., Corbin A.S., et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006, 66:11156-11165.
29. Lacout C., Pisani D.F., Tulliez M., et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108:1652-1660.
30. Li J., Spensberger D., Ahn J.S., et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010, 116(9):1528-1538.
31. Marty C., Lacout C., Martin A., et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010, 116(5):783-787.
32. Mullally A., Lane S.W., Ball B., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17:584-596.
33. Shide K., Shimoda H.K., Kumano T., et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008, 22:87-95.
34. Tiedt R., Hao-Shen H., Sobas M.A., et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111:3931-3940.
35. Wernig G., Mercher T., Okabe R., et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274-4281.
36. Xing S., Wanting T.H., Zhao W., et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008, 111:5109-5117.
37. Zaleskas V.M., Krause D.S., Lazarides K., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006, 1:e18.
38. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
39. Gu L., Chiang K.Y., Zhu N., et al. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol 2007, 35:957-966.
40. Yan D., Hutchison R.E., Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012, 119(15):3539-3549.
41. Walz C., Ahmed W., Lazarides K., et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice. Blood 2012, 119(15):3550-3560.
42. Al-Shami A., Naccache P.H. Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase. J Biol Chem 1999, 274:5333-5338.
43. Bouscary D., Pene F., Claessens Y.E., et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003, 101:3436-3443.
44. Mizuguchi R., Noto S., Yamada M., et al. Ras and signal transducer and activator of transcription (STAT) are essential and sufficient downstream components of Janus kinases in cell proliferation. Jpn J Cancer Res 2000, 91:527-533.
45. Dawson M.A., Bannister A.J., Gottgens B., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009, 461:819-822.
46. Rinaldi C.R., Rinaldi P., Alagia A., et al. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. Blood 2010, 116(26):6023-6026.
47. Tefferi A., Vaidya R., Caramazza D., et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011, 29:1356-1363.
48. Vaidya R., Sulai N., Rozell S.A., et al. Comprehensive plasma cytokine profiling in polycythemia vera: comparison with myelofibrosis and clinical correlates. Blood 2011, 118:3850. [abstract].
49. Emadi S., Clay D., Desterke C., et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood 2005, 105:464-473.
50. Rameshwar P., Narayanan R., Qian J., et al. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000, 165:2271-2277.
51. Huang W.L., Yeh H.H., Lin C.C., et al. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol Cancer 2010, 9:309.
52. Jedidi A., Marty C., Oligo C., et al. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 2009, 114:1842-1851.
53. Manshouri T., Estrov Z., Quintas-Cardama A., et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011, 71:3831-3840.
54. Chen E., Beer P.A., Godfrey A.L., et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010, 18:524-535.
55. Quintas-Cardama A., Vaddi K., Liu P., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
56. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
57. Tefferi A., Barosi G., Mesa R.A., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
58. Verstovsek S., Kantarjian H.M., Estrov Z., et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy. Blood 2011, 118:793. [abstracts].
59. Tefferi A., Litzow M.R., Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011, 365:1455-1457.
60. Verstovsek S., Mesa R.A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
61. Harrison C., Kiladjian J.J., Al-Ali H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
62. Tefferi A., Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011, 86:1188-1191.
63. Wernig G., Kharas M.G., Okabe R., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13:311-320.
64. Lasho T.L., Tefferi A., Hood J.D., et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008, 22:1790-1792.
65. Pardanani A., Gotlib J.R., Jamieson C., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011, 29:789-796.
66. Tyner J.W., Bumm T.G., Deininger J., et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010, 115:5232-5240.
67. Pardanani A., Lasho T., Smith G., et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009, 23:1441-1445.
68. Pardanani A., Gotlib J., Gupta V., et al. An expanded multicenter phase I/II study of CYT387, a JAK- 1/2 inhibitor for the treatment of myelofibrosis. Blood 2011, 118:3849. [abstract].
69. Verstovsek S., Deeg H.J., Odenike O., et al. Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. Blood 2010, 116:3082. [abstract].
70. Deeg H.J., Odenike O., Scott B.L., et al. Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. J Clin Oncol 2011, 29:6515. [abstract].
71. Ma L., Zhao B., Walgren R., et al. Efficacy of LY2784544, a small molecule inhibitor selective for mutant jak2 kinase, in JAK2 V617F-induced hematologic malignancy models. Blood 2010, 116:4087. [abstract].
72. Verstovsek S., Mesa R.A., Rhoades S.K., et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2011, 118:2814. [abstract].
73. Nakaya Y., Shide K., Niwa T., et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J 2011, 1:e29.
74. Purandare A.V., McDevitt T.M., Wan H., et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012, 26:280-288.
75. Alvarez-Larran A., Pereira A., Cervantes F., et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 2012, 119:1363-1369.
76. Antonioli E., Guglielmelli P., Pieri L., et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol 2012, 87:552-554.
77. Verstovsek S., Passamonti F., Rambaldi A., et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood 2010, 116:313. [abstract].
78. Barosi G., Birgegard G., Finazzi G., et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009, 113:4829-4833.
79. Deshpande A., Reddy M.M., Schade G.O., et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012, 26:708-715.
80. Bhagwat N., Koppikar P., Kilpivaara O., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Blood 2011, 118:122. [abstract].
81. Weigert O., Lane A.A., Bird L., et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012, 209:259-273.